<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004039</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000066762</org_study_id>
    <secondary_id>CBRG-9807</secondary_id>
    <secondary_id>NCI-V98-1494</secondary_id>
    <nct_id>NCT00004039</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy Plus Interferon Alfa or Rituximab in Treating Patients With Stage III or Stage IV Lymphoma</brief_title>
  <official_title>Phase II Trials of CHOP Chemotherapy and Interferon Alpha or Rituximab Anti-CD20 Monoclonal Antibody as Initial Treatment of Patients With Stage III and IV High-Risk Indolent B-Cell Lymphoma and Intermediate Grade B-Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoag Memorial Hospital Presbyterian</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cancer Biotherapy Research Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hoag Memorial Hospital Presbyterian</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing
      so they stop growing or die. Combining interferon alfa or the monoclonal antibody rituximab
      with chemotherapy may kill more cancer cells.

      PURPOSE: Phase II trial to compare the effectiveness of combination chemotherapy plus
      interferon alfa or rituximab in treating patients who have high risk stage III or stage IV
      lymphoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine the toxicity of cyclophosphamide, doxorubicin, vincristine, and
      prednisone (CHOP) with either interferon alfa or rituximab in patients with stage III or IV
      high risk indolent or intermediate B-cell lymphoma. II. Determine the objective tumor
      response rate and duration of response for these regimens in these patients. III. Determine
      the failure free survival and overall survival for these patients on these regimens. IV.
      Compare the response rate and survival rate of these patients on these regimens to similar
      patients treated in published studies. V. Compare the toxicities of these regimens in these
      patients. VI. Determine the quality of life of these patients on these regimens.

      OUTLINE: This is a multicenter study. Patients are assigned to one of two treatment arms: Arm
      I: Patients receive rituximab IV on day 0, and cyclophosphamide IV, doxorubicin IV, and
      vincristine IV on day 1, followed by oral prednisone on days 1-5. Arm II: Patients receive
      interferon alfa subcutaneously on days 22-26, and cyclophosphamide IV, doxorubicin IV, and
      vincristine IV on day 1, followed by oral prednisone on days 1-5. Treatment repeat every 28
      days for up to 8 courses in the absence of disease progression or unacceptable toxicity.
      Quality of life is assessed at baseline and prior to chemotherapy for each course. Patients
      are followed every 3 months for 2 years, every 6 months for 2 years, and then annually for up
      to 10 years.

      PROJECTED ACCRUAL: A total of 40-80 patients (20-40 per treatment arm) will be accrued for
      this study.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    No patient accruals
  </why_stopped>
  <start_date>June 1998</start_date>
  <completion_date type="Actual">January 2000</completion_date>
  <primary_completion_date type="Actual">January 2000</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Actual">0</enrollment>
  <condition>Lymphoma</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>recombinant interferon alfa</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rituximab</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisone</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vincristine sulfate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Histologically confirmed high risk (stage III or IV) indolent or
        intermediate (stage II to IV) B-cell lymphoma Small cleaved cell lymphoma Waldenstrom's
        macroglobulinemia Follicular small cleaved cell or mixed cell Follicular large cell Diffuse
        Immunoblastic High risk is defined as: Increased LDH OR Increased beta-2-microglobulin OR B
        symptoms OR Bulky disease of greater than 7 cm in diameter OR Extranodal disease other than
        blood or bone marrow involvement OR Mantle zone histology At least 1 lymph node or visceral
        lesion at least 2 cm in diameter

        PATIENT CHARACTERISTICS: Age: Not specified Performance status: ECOG 0-2 Life expectancy:
        Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified
        Other: No active infection or other medical condition this is lifethreatening Not pregnant
        Fertile patients must use effective contraception

        PRIOR CONCURRENT THERAPY: No prior therapy for lymphoma
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert O. Dillman, MD, FACP</last_name>
    <role>Study Chair</role>
    <affiliation>Cancer Biotherapy Research Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hoag Memorial Hospital Presbyterian</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92658</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 10, 1999</study_first_submitted>
  <study_first_submitted_qc>August 4, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 5, 2004</study_first_posted>
  <last_update_submitted>August 17, 2015</last_update_submitted>
  <last_update_submitted_qc>August 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 19, 2015</last_update_posted>
  <responsible_party>
    <name_title>Robert O. Dillman, MD</name_title>
    <organization>Hoag Memorial Hospital Presbyterian</organization>
  </responsible_party>
  <keyword>Waldenstrom macroglobulinemia</keyword>
  <keyword>stage II grade 3 follicular lymphoma</keyword>
  <keyword>stage II adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage II adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage II adult diffuse large cell lymphoma</keyword>
  <keyword>stage II adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage II adult Burkitt lymphoma</keyword>
  <keyword>stage III grade 1 follicular lymphoma</keyword>
  <keyword>stage III grade 2 follicular lymphoma</keyword>
  <keyword>stage III grade 3 follicular lymphoma</keyword>
  <keyword>stage III adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage III adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage III adult diffuse large cell lymphoma</keyword>
  <keyword>stage III adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage III adult Burkitt lymphoma</keyword>
  <keyword>stage IV grade 1 follicular lymphoma</keyword>
  <keyword>stage IV grade 2 follicular lymphoma</keyword>
  <keyword>stage IV grade 3 follicular lymphoma</keyword>
  <keyword>stage IV adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage IV adult diffuse large cell lymphoma</keyword>
  <keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage IV adult Burkitt lymphoma</keyword>
  <keyword>stage III mantle cell lymphoma</keyword>
  <keyword>stage IV mantle cell lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

